Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency

• Published in: BMC veterinary research 2020-07, Vol.16 (1), p.259-259, Article 259
• Main Authors: Oh, Yeonsu, Kim, Jung Ae, Kim, Chang-Hwan, Choi, Soo-Keun, Pan, Jae-Gu
• Format: Article
• Language: English
• Subjects: Adjuvanticity; Animal models; Animals; Anthrax; Anthrax - prevention & control; Anthrax vaccines; Anthrax Vaccines - administration & dosage; Anthrax Vaccines - pharmacology; Antibodies; Antibodies, Neutralizing - blood; Antigens; Antigens, Bacterial - immunology; Bacillus; Bacillus anthracis; Bacillus subtilis; Bacillus subtilis - immunology; Bacterial spores; Bacterial Toxins - immunology; Composition; Developing countries; Health aspects; Immunization; Immunoglobulin A; LDCs; Male; Mice; Mucosa; Mucosal vaccine; Native display; Physiological aspects; Probiotics; Protective antigen; Proteins; Saliva; Saliva - immunology; Spore; Spores; Spores, Bacterial - immunology; Testing; Titration; Vaccines; Vaccines, Synthetic; Virulence factors
• ISSN: 1746-6148; 1746-6148
• DOI: 10.1186/s12917-020-02468-3

Bacillus anthracis is the causative agent of anthrax, a disease of both humans and various animal species, and can be used as a bioterror agent. Effective vaccines are available, but those could benefit from improvements, including increasing the immunity duration, reducing the shot frequency and adverse reactions. In addition, more sophisticated antigen delivery and potentiation systems are urgently required. The protective antigen (PA), one of three major virulence factors associated with anthrax was displayed on the surface of Bacillus subtilis spores, which is a vaccine production host and delivery vector with several advantages such as a low production cost, straightforward administration as it is safe for human consumption and the particulate adjuvanticity. Mice were immunized orally (PO), intranasally (IN), sublingually (SL) or intraperitoneally (IP) with the PA displaying probiotic spore vaccine. Clinical observation, serological analysis and challenge experiment were conducted to investigate the safety and efficacy of the vaccine. A/J mice immunized with the PA spore vaccine via PO, IN, SL, and IP were observed to have increased levels of active antibody titer, isotype profiles and toxin neutralizing antibody in sera, and IgA in saliva. The immunized mice were demonstrated to raise protective immunity against the challenge with lethal B. anthracis spores. In this study, we developed a B. subtilis spore vaccine that displays the PA on its surface and showed that the PA-displaying spore vaccine was able to confer active immunity to a murine model based on the results of antibody isotype titration, mucosal antibody identification, and a lethal challenge experiment.